State Street Holds 5.2% Of CRISPR Therapeutics Without Seeking To Influence Control

The holding covered nearly 5 million shares as of September 30, while CRISPR's experimental triglyceride treatment remains at an early stage.

Share
State Street Holds 5.2% Of CRISPR Therapeutics Without Seeking To Influence Control

State Street held a 5.2% passive stake in CRISPR Therapeutics, which develops gene-based medicines for serious diseases, according to an SEC ownership disclosure filed Tuesday. The position comprised 4,994,047 common shares—nearly 5 million—as of September 30.

Voting Power Without A Control Bid

State Street certified that the holding arose from its ordinary business activities and that it was not seeking to change or influence CRISPR's control. The disclosure describes ownership at the September 30 reporting date rather than purchases on Tuesday.

State Street had shared voting authority over 4,737,614 shares and shared authority to dispose of all 4,994,047 shares. It reported no sole voting or disposal authority.

CRSP shares returned about 5% this year through Monday, compared with about 10% for the S&P 500. CRISPR's market value was $4.9 billion as of 7:11 a.m. ET Tuesday.

CTX310's Early Results, CASGEVY's Commercial Base

CRISPR reported Monday that its experimental CTX310 treatment produced a mean 63% triglyceride reduction after 30 days in an early-stage study of patients with severely elevated triglycerides. The severe-triglyceride cohort included 10 participants.

The company's most advanced medicine is CASGEVY, which treats eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia. CRISPR develops and sells it jointly with Vertex Pharmaceuticals, which leads commercialization. The treatment has approvals in the United States, the European Union, Great Britain, Canada, Switzerland and several Middle Eastern countries.

CRISPR uses CRISPR/Cas9 editing to alter targeted DNA sequences. Its research spans blood disorders, editing delivered directly into the body, CAR T cell therapies and regenerative medicine for Type 1 diabetes. It also works with Sirius Therapeutics on siRNA medicines and operates a manufacturing facility in Framingham, Massachusetts.

The CTX310 findings concern a 10-participant cohort; State Street's disclosure concerns a passive ownership position, with no stated aim to influence company control.

Sources

More on CRISPR Therapeutics

All CRISPR Therapeutics (CRSP) coverage →